HBT-708

HBT-708 is a biological product under investigation as a monotherapy for the treatment of advanced solid tumors. It is being evaluated in phase 1 clinical trials with primary focus on assessing its safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary antitumor efficacy in patients with advanced malignant solid neoplasms. Dosing is administered intravenously every three weeks. The drug is in early clinical development, and detailed information about its precise biological mechanism of action or specific molecular target has not yet been made publicly available. The development involves dose escalation to determine the maximum tolerated dose and to establish dosing recommendations for future trials. Exploratory objectives include evaluating the relationship between PD-L1 expression and efficacy in tumor specimens[1][2][7][10].